AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05460065
Drug: multiple E4 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
Trial: NCT05460065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)
Trial: NCT06442280
Drug: Hypertonic Saline Solution, 1 Ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Trial: NCT06246175
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HRS9531 injection
Trial: NCT05456269
Drug: Decitabine and cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
Trial: NCT05221580
Drug: Ryzodeg®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Trial: NCT05253846
Drug: Lederfolin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment
Trial: NCT05306418
Drug: Mim8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin
Trial: NCT04879628
Drug: placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: IV infusion
Trial: NCT04879628
Drug: placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: SC injection
Trial: NCT05903820
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch of estradiol
Trial: NCT02233257
Drug: Lorenzo's Oil
RxNorm normalized name: LORENZO'S OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use of Lorenzo's oil to lower very long chain fatty acids
Trial: NCT05793736
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
Trial: NCT05324735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive placebo (orally ingested) twice a day for 12 weeks.
Trial: NCT04972656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning.
Trial: NCT05251493
Drug: Iron Isomaltoside 1000, ferric derisomaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iron isomaltoside 20 mg/mL
Trial: NCT05984537
Drug: standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
Trial: NCT04909723
Drug: NB2000P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A botanically derived polysaccharide.
Trial: NCT04909723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04807413
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
Trial: NCT04810962
Drug: APP13007, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APP13007 eye drop, 0.05%
Trial: NCT04810962
Drug: Matching Vehicle Placebo for APP13007, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle placebo eye drop
Trial: NCT06135714
Drug: Systemic therapy for 12 weeks after primary registration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Trial: NCT06135714
Drug: Same systemic therapy after secondary registration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Trial: NCT05463861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Lemborexant tablet administered orally once daily.
Trial: NCT05700591
Drug: rhPro-UK
RxNorm normalized name: Vital E- Repro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
Trial: NCT05733572
Drug: CHF6467
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug eyedrops
Trial: NCT05733572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo eyedrops
Trial: NCT05939674
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
Trial: NCT04083170
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05998863
Drug: EffCaMgCit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Trial: NCT04939116
Drug: ANG-3070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered tyrosine kinase inhibitor capsule
Trial: NCT04939116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered placebo capsule
Trial: NCT05658120
Drug: noradrenaline/adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
Trial: NCT05248867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for injection
Trial: NCT05248867
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-151586 solution for injection
Trial: NCT05035654
Drug: LYR-220 Design 2 (Part 1 and Part 2)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Trial: NCT05035654
Drug: Bilateral sham procedure control (Part 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sham procedure control
Trial: NCT00012857
Drug: acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05664737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04711005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
Trial: NCT05201690
Drug: VV116 200 mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
Trial: NCT05201690
Drug: VV116 400mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
Trial: NCT05201690
Drug: VV116 600mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
Trial: NCT05065645
Drug: Angiotensin Converting Enzyme 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: single dose; MAD: dosage 2x daily for 7 days
Trial: NCT04999787
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
Trial: NCT04999787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05641909
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil
Trial: NCT05641909
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Trial: NCT04799990
Drug: Comparator 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, Opthalmic, Subcutaneous or Intravenous Injection
Trial: NCT05525468
Drug: TDM-180935
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-180935 topical ointment
Trial: NCT05525468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for TDM-180935 topical ointment
Trial: NCT05875571
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will get IV ketorolac during IUD placement under sedation
Trial: NCT05875571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will get IV placebo during IUD placement under sedation
Trial: NCT05413642
Drug: Recommended treatment schedule
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Trial: NCT05413642
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Trial: NCT04808544
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Trial: NCT05944887
Drug: Saline administration as placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of a bolus of saline solution as a placebo
Trial: NCT03629093
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
Trial: NCT04424602
Drug: cyclo phosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg vial
Trial: NCT04655599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Trial: NCT05638087
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Mix
Trial: NCT04660539
Drug: azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
Trial: NCT04660539
Drug: oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
Trial: NCT06310551
Drug: Oral VH4524184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4524184 to be taken orally.
Trial: NCT06310551
Drug: Placebo Formulation A SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of Placebo Formulation A administered subcutaneously.
Trial: NCT06310551
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of rHuPH20 administered subcutaneously.
Trial: NCT06310551
Drug: VH4524184 Formulation B SC
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
Trial: NCT06310551
Drug: Placebo Formulation B SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of Placebo Formulation B administered subcutaneously.
Trial: NCT06310551
Drug: Placebo Formulation C SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of Placebo Formulation C administered subcutaneously.
Trial: NCT06310551
Drug: Placebo Formulation A IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of Placebo Formulation A administered intramuscularly.
Trial: NCT06310551
Drug: VH4524184 Formulation B IM
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose VH4524184 LAI Formulation B administered intramuscularly.
Trial: NCT06310551
Drug: Placebo Formulation B IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of Placebo Formulation B administered intramuscularly.
Trial: NCT05237596
Drug: Glucosamine Sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
Trial: NCT05786066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered 2.5 hours before Ketamine infusion
Trial: NCT05167864
Drug: Onabotulinumtoxina for Injection
RxNorm normalized name: Onabotulinumtoxina for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cosmetic injection into the glabella area (eyebrow area)
Trial: NCT05167864
Drug: PrabotulinumtoxinA for Injection
RxNorm normalized name: prabotulinumtoxinA-xvfs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cosmetic injection into the glabella area (eyebrow area)
Trial: NCT04852003
Drug: SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 Injection
Trial: NCT04852003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for SHR0410 Injection
Trial: NCT05780541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution
Trial: NCT05786417
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection of the specific BB and initial starting dose will be determined by the treating clinician.
Trial: NCT05786417
Drug: Calcium channel blocker
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
Trial: NCT05880043
Drug: GIC-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
Trial: NCT04729517
Drug: AI201901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily inhaled AI201901 for 4 weeks
Trial: NCT06240390
Drug: pharmacological treatment by Opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
Trial: NCT05326516
Drug: Chemotherapy Regimen 1
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
Trial: NCT05326516
Drug: Chemotherapy Regimen 2
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
Trial: NCT06361433
Drug: HUFF-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous MSC combined with scaffold
Trial: NCT05267886
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline running at a standardized rate
Trial: NCT04746339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily for 30 days
Trial: NCT06254248
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept.
Trial: NCT06082323
Drug: LT-002-158/Placebo oral tablet(s)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Trial: NCT05227703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Trial: NCT05394116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Trial: NCT05176470
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05772520
Drug: TLL018 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Trial: NCT06210607
Drug: HS-10511 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
Trial: NCT06402851
Drug: Anticoagulant Oral
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Trial: NCT06153966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching ION717 will be administered by IT injection.
Trial: NCT06533748
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT06533748
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, PO or intramuscular (IM).
Trial: NCT06514963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06267001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered IV.
Trial: NCT04860830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo